Key result
Concurrent chemoradiation caused a dose-dependent reduction in left and right ventricular ejection fractions (mean reduction 5.6% and 6.5%, respectively; p=0.001).
Why the study?
Does concurrent chemoradiation reduce cardiac contractility in patients with locally advanced oesophageal squamous cell carcinoma?
Observational (n=16)
Does concurrent chemoradiation reduce cardiac contractility in patients with locally advanced oesophageal squamous cell carcinoma?
p-value: p=0.001
Concurrent chemoradiation in esophageal cancer leads to an acute, dose-dependent reduction in biventricular ejection fraction, particularly during the boost phase.
Acute EF decline during chemoradiation warrants serial monitoring; leaves open optimal heart dose thresholds to prevent clinical cardiotoxicity.
OBJECTIVE: To study the acute effects of concurrent chemoradiation on global and regional cardiac contractility and correlate with radiation dose. METHODS: 16 patients of locally advanced oesophageal squamous cell carcinoma were serially followed up with multiple-gated acquisition (MUGA) scans and echocardiograms during the course of concurrent chemoradiation to evaluate the ejection fractions (EFs) and pericardial status, respectively. Changes in cardiac contractility were correlated with the doses received by the heart. RESULTS: Concurrent chemoradiation resulted in a significant reduction in the contractility of both left ventricle (LV) and right ventricle (RV), with a mean reduction of LVEF by 5.6% and RVEF by 6.5% over the course of treatment, which had a significant correlation with the radiation doses received by the ventricles (p=0.001). On further analysis, correlation between radiation dose and decrease in contractility was more significant in the boost phase (16 Gy in 8 fractions over one and a half weeks; p=0.001 for LV and p=0.008 for RV) compared with the initial phase (40 Gy in 20 fractions over 4 weeks; p=0.184 for LV and p=0.269 for RV). One out of 16 patients developed mild acute pericarditis. CONCLUSIONS: Concurrent chemoradiation resulted in acute decrease in EF of both ventricles in a dose-dependent manner. Correlation between cardiac doses and decrease in EF was more marked in the boost phase, suggesting a possible threshold of 40 Gy for this impairment. Nevertheless, conclusions regarding this possible threshold need to be interpreted with caution given the small sample size.
No takes yet. Share an insight, caveat, or question.
Miriyala et al. (2015) conducted an observational in Locally advanced oesophageal squamous cell carcinoma (n=16). Concurrent chemoradiation was evaluated on Changes in global and regional cardiac contractility (ejection fractions) correlated with radiation dose (p=0.001). Concurrent chemoradiation caused a dose-dependent reduction in left and right ventricular ejection fractions (mean reduction 5.6% and 6.5%, respectively; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: